Net Net Stock Overview

Subscribe

To see hundreds more international net nets, consider subscribing

Overview

Singular Genomics Systems Inc
Healthcare
P/NCAV
0.29x
Ticker
OMIC
Exchange
NASDAQ
Country
United States
Close
0.41 $
Mkt Cap
30.2M $
EV
22.8M $
NCAV Burn Rate
47.3%
Current Ratio
10.51
Debt/Equity
0.05
EV/REV
7.84x
EV/EBIT
-0.2x
EV/FCF
-0.3x
Dilution
1.2% p.A
Total Net Income
-324.7M $
Cheapness
100.0%
Singular Genomics Systems, Inc. is a life science technology company that develops next-generation sequencing (NGS) and multiomics technologies. The Company has developed NGS technology (Sequencing Engine), which is a platform technology for its products. The core of its Sequencing Engine consists of proprietary chemistry, including novel chemical compounds, polymers, and enzymes. Its active product development pipeline consists of two products, each of which is designed to leverage the Sequencing Engine and purpose-built to address different applications. Its first product, the G4 Sequencing Platform (G4), targets the NGS market. Its second product in development, G4X Spatial Sequencer, which leverages its sequencing technology, applying it as an in-situ readout for transcriptomics, proteomics and fluorescent H+E in tissue, with spatial context and on the same platform as the G4. The Company is also engaged in developing PX, which is a development-stage multiomics platform.

Profitability

positive values --- Average negative values

Margins

--- Average

Valuation

positive values --- Average negative values

Dilution

--- Average